On this page
Quick answer
medicines require medical assessment and a prescription. They can cause digestive effects and have precautions depending on the medicine and clinical history. Indication and follow-up cannot be decided by a wellbeing questionnaire.
Educational information for adults. This is not a prescription or an individual medical assessment. Longevity Online is a wellbeing plan: it does not include medicines or obesity treatment. GLP‑1 use requires a medical indication, prescription and healthcare follow-up.
Medical terms, explained
Hover, use keyboard focus or tap an underlined word to see its meaning.
Read all definitions
- GLP-1
- Glucagon-like peptide-1: a gut hormone involved in insulin release after eating and appetite regulation. Source
- GIP
- Glucose-dependent insulinotropic polypeptide: a gut hormone that helps release insulin in response to food. Source
- BMI
- Body mass index: weight in kilograms divided by height in metres squared. An indicative measure, not a measure of body composition. Source
- Waist/height
- Waist circumference divided by height in the same units. Helps assess central adiposity alongside BMI; it is not a diagnosis. Source
What is checked before a treatment decision?
Assessment includes weight-related complications, current treatments and relevant history. For certain medicines authorised for weight management, EMA lists adult criteria of 30 or above, or 27 or above with at least one weight-related condition.
Meeting a threshold does not make a medicine suitable. Pregnancy, breastfeeding, digestive history and other circumstances require assessment against current product information.
What adverse effects can occur?
Nausea, vomiting, diarrhoea and constipation are among the digestive effects of these treatments. Frequency and severity vary. There are also warnings about pancreatitis, gallbladder problems and dehydration; hypoglycaemia risk depends, among other factors, on combination with certain diabetes treatments.
Severe persistent abdominal pain, vomiting that prevents drinking or signs of an allergic reaction need medical attention. Semaglutide product information also lists a very rare optic neuropathy: sudden loss or rapidly worsening vision needs immediate medical attention. This medicine-specific warning is not automatically attributed to tirzepatide. This is safety information, not a complete list: the leaflet and product information give medicine-specific precautions.
What should you ask the healthcare team?
Ask about treatment goals, the follow-up required, warning signs and how tolerance will be assessed. Discuss medicines you already use and any planned procedure involving anaesthesia or sedation.
Do not buy medicines from unknown sources or adjust doses, combine medicines or stop treatment based on this guide. Marketing and social media do not replace medical indication.
BMI and waist-to-height ratio
An indicative tool for adults aged at least 18 who are not pregnant. Enter height and weight; waist measurement is optional. All length measurements must be in centimetres (cm).
Calculated on this device. These measurements are not saved or sent anywhere.
These results are neither a diagnosis nor a probability of disease. No number alone indicates treatment with GLP-1 or any other medicine; decisions require clinical assessment.
How to read these numbers
This tool excludes people under 18 and pregnant people. BMI does not distinguish fat from muscle: high muscle mass can affect its interpretation. For adults over 65, function, nutritional status and other circumstances must be considered. Clinical context and ethnic background also matter: no universal BMI classification is applied here to everyone.
NICE NG246 uses waist-to-height ratio alongside BMI in adults with BMI <35. Its bands are a central adiposity reference, not an assessment of overall health.
Technical validation limits: height 100–250 cm, weight 20–400 kg and waist 30–250 cm. These are not clinical cut-offs and do not define what is healthy; consult a professional if your measurements fall outside them.
Source: NICE NG246 · recommendations 1.9.5, 1.9.8, 1.9.14 and 1.9.15 (Opens in a new tab)
2025 guideline · checked on 10 November 2026.
Frequently asked questions
Can BMI tell me whether I need a GLP‑1 medicine?
No. is one criterion in certain authorisations, but decisions also depend on complications, history, contraindications, other treatments and follow-up.
Are they used during pregnancy?
WHO excludes pregnant women from its obesity recommendation. Pregnancy, pregnancy planning and breastfeeding must be discussed with healthcare professionals for the specific medicine.
Where can I get a dosing schedule?
Dosing is the responsibility of the prescriber and depends on the authorised medicine. This website does not provide doses, escalation schedules or combinations.
Original sources
Source publication date or date regulatory information was checked.
- EMA · regulatory information on GLP-1 medicines(Opens in a new tab)
Información regulatoria consultada
https://www.ema.europa.eu/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists
- EMA · regulatory information on GLP-1 medicines(Opens in a new tab)
Información regulatoria consultada
https://www.ema.europa.eu/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists
- EMA · Appropriate use of GLP-1 receptor agonists(Opens in a new tab)
2024-06-26
https://www.ema.europa.eu/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists
- WHO · Global guideline on GLP-1 medicines and obesity(Opens in a new tab)
2025-12-01
https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity